Is venetoclax/venetoclax a medically insured drug?

Venetoclax/Venetoclax is an important innovative drug for the treatment of specific types of leukemia and lymphoma. Its status as the world's first BCL-2 (B lymphocytoma-2 gene) inhibitor gives it a prominent position in the pharmaceutical field. As an innovative drug, venetoclax has been widely recognized for its efficacy in the treatment of leukemia. However, due to its high research and development costs, the drug price is relatively expensive, which is also one of the important factors affecting its inclusion in medical insurance.

The active ingredient in venetoclaxvenetoclax attaches to a protein called Bcl-2. This protein, found in large amounts in leukemia cancer cells, helps the cells survive longer in the body and makes them resistant to cancer drugs. Venetoclax slows the progression of the disease by binding to Bcl-2 and blocking its action, causing cancer cells to die. Venetextra should be taken under the supervision of a doctor experienced with cancer drugs and is only available by prescription.

Although venetoclax has been marketed in China and has been approved by the National Medical Products Administration for the treatment of specific types of leukemia, it is currently not used alone in clinical guidelines, but is mainly used in combination with azacitidine (Azacitidine) to treat adult acute myeloid leukemia (AML). Moreover, Venetoclax can be found in the Category B medical insurance directory, but it is only reimbursed by medical insurance for patients who meet the indications.

Therefore, not all patients who use Veneclatra can enjoy reimbursement benefits from medical insurance, and the reimbursement ratios are different in different regions. The price after reimbursement may be different. For specific reimbursement policies, you need to consult the local medical insurance bureau and other places.